Related Experiment Video
Updated: Aug 18, 2026

Myocardial Infarction by Percutaneous Embolization Coil Deployment in a Swine Model
Published on: November 4, 2021
[Pulmonary hemorrhage after abciximab. Risk factors and the role of protamine]
Francisco J Rodríguez-Gómez1, Angel Sánchez, Francisco J Martínez
1Servicio de Medicina Interna, Hospital Juan Ramón Jiménez, Huelva, España. med007369@saludalia.com
Abstract:
Large clinical trials have demonstrated the clinical effectiveness of therapy with inhibitors of the platelet surface-membrane glycoprotein IIb-IIIa receptor in a broad range of patients with ischemic heart disease. Abciximab, a platelet glycoprotein IIb-IIIa receptor blocker, is associated with improved long-term prognosis in patients who require angioplasty and stent placement. Severe bleeding from abciximab use is an uncommon event. We describe a patient with severe pulmonary hemorrhage after treatment with abciximab, and discuss predisposing factors and protamine infusion in this potentially fatal complication.
Related Concept Videos
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Pulmonary Embolism III: Nursing Management
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism I: Introduction
Pulmonary Embolism I: Introduction